McKesson Corporation Reports Strong Q2 2026 Results and Raises Full Year Guidance

Details

The company's consolidated revenues rose to a record high of $103.2 billion, a 10% increase from the prior year. McKesson also saw a substantial increase in earnings per diluted share, from $1.87 to $8.92. Adjusted Earnings per Diluted Share also improved by 39%, from $7.07 to $9.86. The company generated $2.4 billion in cash flow from operations and $2.2 billion in Free Cash Flow. McKesson has raised its fiscal 2026 Adjusted Earnings per Diluted Share guidance range to $38.35 to $38.85, indicating a 16% to 18% growth compared to the prior year.

Items reported

About McKesson Corporation

McKesson Corporation is a leading healthcare services and information technology company. It plays a crucial role in the distribution of pharmaceuticals and medical products. The primary function of McKesson is to ensure the efficient delivery of healthcare products to pharmacies, hospitals, and other medical facilities, ensuring that millions of patients have access to the medications they need. It also provides specialized software and automated solutions that enhance operational efficiency in healthcare sectors. McKesson significantly impacts the pharmaceutical and healthcare industries by offering solutions that streamline supply chains and improve patient care. Its services encompass wholesale drug distribution, healthcare IT systems, and pharmacy management. With operations that extend globally, McKesson is integral to maintaining the integrity and reliability of healthcare supply networks. By handling a substantial portion of the pharmaceutical distribution in North America, McKesson Corporation has a vital market presence, emphasizing its importance in shaping healthcare logistics and innovation. Its efforts contribute to advancing healthcare delivery and responding to the evolving demands of the medical industry.